The story of copyright's flagship drug presents a interesting case for investors in the medicinal sector. While initially a tremendous success, generating billions, the patent expiration and the subsequent flood of generic alternatives have significantly impacted earnings. This poses questions about the ongoing sustainability of similar therapeu… Read More